News

Ambrilia has reported the termination of the phase III clinical Study 303. The move is in line with the company’s ongoing measures to effectively reduce costs. Reportedly, study

UCB has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA), for Keppra. Reportedly, the positive opinion

Compass Pharma has completed a capital investment project to upgrade its production capabilities to include ISO Class 8 (ISO 14644) specifications, so as to provide packaging services for

In order to provide contract pharmaceutical packaging services for certain high-potency pharmaceutical products, Compass Pharma Services has announced the completion of a capital investment project to upgrade its

CytRx’s drug candidate, tamibarotene has received official notification from the Committee for Orphan Medicinal Products (COMP) of the EMEA. Reportedly, a positive opinion was made regarding the application

Aurobindo has received the final approval for Zidovudine Tablets 60mg (NDA 22-294) and tentative approval for Lamivudine & Zidovudine Tablets 30mg/60mg(NDA 22-296) from the US Food and Drug

Kinetic Concepts has reported that the US Patent and Trademark Office (USPTO) has issued office actions confirming the validity of three separate patents licensed to KCI by Wake

The EU’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of Roche’s MabThera (rituximab) in patients with relapsed or refractory chronic lymphocytic

SeattleGenetics has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the re-treatment of patients with Hodgkin lymphoma and systemic anaplastic large